Crizanlizumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Crizanlizumab. Educational only — not medical advice.
Labeled uses
ADAKVEO® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
Source: FDA labeling via NIH DailyMed (set b2b7f8b4…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.